Sepracor Resubmits Estorra NDA; Expected Approval Pushed To Year-End

The company expects FDA will take six months to review the eszopiclone resubmission. Sepracor had earlier expressed optimism about a two-month review, which would have set an approval target for the sleep agent around mid-year.